Ionis Pharmaceuticals (IONS) Expected to Release Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS) is projected to announce its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect Ionis Pharmaceuticals to announce earnings of ($1.0810) per share and revenue of $189.0960 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:30 AM ET.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.29. The firm had revenue of $246.09 million for the quarter, compared to the consensus estimate of $195.56 million. Ionis Pharmaceuticals had a negative net margin of 30.91% and a negative return on equity of 58.65%. The business’s revenue was up 86.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.93) earnings per share. On average, analysts expect Ionis Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ionis Pharmaceuticals Stock Performance

Shares of Ionis Pharmaceuticals stock opened at $56.55 on Monday. Ionis Pharmaceuticals has a 52-week low of $40.03 and a 52-week high of $86.74. The firm has a market capitalization of $9.35 billion, a PE ratio of -27.32 and a beta of 0.36. The company has a debt-to-equity ratio of 2.75, a current ratio of 4.10 and a quick ratio of 4.09. The company’s fifty day moving average price is $71.60 and its two-hundred day moving average price is $75.49.

Insider Activity at Ionis Pharmaceuticals

In related news, EVP C Frank Bennett sold 5,536 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $83.58, for a total transaction of $462,698.88. Following the completion of the sale, the executive vice president directly owned 75,018 shares of the company’s stock, valued at $6,270,004.44. This trade represents a 6.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Brett P. Monia sold 50,000 shares of the business’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $80.59, for a total value of $4,029,500.00. Following the completion of the transaction, the chief executive officer directly owned 245,571 shares in the company, valued at approximately $19,790,566.89. This represents a 16.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 233,163 shares of company stock valued at $18,316,551. Insiders own 1.81% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MetLife Investment Management LLC raised its holdings in Ionis Pharmaceuticals by 2.6% during the 4th quarter. MetLife Investment Management LLC now owns 9,674 shares of the company’s stock worth $765,000 after purchasing an additional 246 shares during the last quarter. Public Employees Retirement System of Ohio increased its stake in Ionis Pharmaceuticals by 0.6% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 48,545 shares of the company’s stock worth $3,176,000 after purchasing an additional 301 shares in the last quarter. Mackenzie Financial Corp increased its position in shares of Ionis Pharmaceuticals by 8.4% during the fourth quarter. Mackenzie Financial Corp now owns 3,891 shares of the company’s stock worth $307,000 after acquiring an additional 303 shares in the last quarter. Brown Brothers Harriman & Co. acquired a new stake in shares of Ionis Pharmaceuticals in the 4th quarter valued at about $27,000. Finally, Vanguard Personalized Indexing Management LLC raised its position in Ionis Pharmaceuticals by 3.1% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 12,461 shares of the company’s stock valued at $986,000 after buying an additional 371 shares during the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Wall Street Analyst Weigh In

IONS has been the subject of several recent research reports. Canaccord Genuity Group dropped their price target on shares of Ionis Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating for the company in a research report on Friday, July 10th. Royal Bank Of Canada lowered their price objective on Ionis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Oppenheimer reissued an “outperform” rating and issued a $111.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday, April 30th. Needham & Company LLC cut their target price on Ionis Pharmaceuticals from $105.00 to $86.00 and set a “buy” rating for the company in a research report on Thursday, July 9th. Finally, Wolfe Research reaffirmed a “peer perform” rating on shares of Ionis Pharmaceuticals in a research note on Thursday, July 16th. Eighteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Ionis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.90.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.